ME02191B - Protutijela koja neutraliziraju ljudski čimbenik stimuliranja kolonija makrofaga - Google Patents
Protutijela koja neutraliziraju ljudski čimbenik stimuliranja kolonija makrofagaInfo
- Publication number
- ME02191B ME02191B MEP-2015-111A MEP11115A ME02191B ME 02191 B ME02191 B ME 02191B ME P11115 A MEP11115 A ME P11115A ME 02191 B ME02191 B ME 02191B
- Authority
- ME
- Montenegro
- Prior art keywords
- set forth
- seq
- amino acid
- acid sequence
- fragment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
Claims (11)
1. Ljudsko monoklonsko protutijela, ili njegov fragment, naznačeno time što sadrži:(a) varijabi lna područje lakog lanca, koje sadrži aminokiselinski slijed kao što je i znijet u SEQ ID NO: 19 i dodatno sadrži varijabi lna područje teškog lanca, koje se bira između:(i) aminokiselinskog slijeda kao što je iznijet u SEQ ID NO: 21; (ii) aminok i selinskog s lijeda kao što je iznijet u SEQ ID NO: 22; (iii)aminokise lin skog slijeda kao što je iznijet u SEQ ID NO: 52; i (iv)aminokise lin skog slijeda kao što je iznijet u SEQ ID NO: 53; ili(b)varijabilno područje l akog lanca, koje sadrži aminokiselinski slijed kao što je iznijet u SEQlD NO: 54 i dodatno sadrži varijabilna područje teškog lan ca, koje se bira između : (i) aminokiselinskog slijeda kao što je iznijet u SEQ ID NO: 23;(ii) aminokiselin skog slijeda kao što je iznijet u SEQ ID NO: 26; i(iii)aminokiselinski s lijed kao što je iznijet u SEQ ID NO: 28;ili(e) varijabi ln a područje l akog lanca, koje sadrži aminokiselinsk i slijed kao što je iznijet u SEQ ID NO: 55 i dodatno sadrži varijabi lna područje teš kog lan ca, koje se bira između:(i) aminokiselinskog slijeda kao što je iznijet u SEQ ID NO: 21; i (ii) aminokiselin skog slijeda kao što je iznijet u SEQ ID NO: 22; ili(d) laki lanac, koji sadrži aminokiselinski slijed kao što je iznijet u SEQ ID NO: 34 i dodatno sadrži teški lanac, koji se bira između:(i) aminokiselinskog slijeda kao što je iznijet u SEQ lD NO: 35; (ii) aminokiselinskog s lijeda kao što je iznijet u SEQ TD NO: 37;(iii)aminokiselinskog slijeda kao što je iznijet u SEQ ID NO: 40; (iv) aminokiselinskog slijeda kao što je iznijet u SEQ ID NO: 42; i (v) aminokiselinskog slijeda kao što je iznijet u SEQ ID NO: 48.
2. Ljudsko monoklonsko protutijela, ili njegov fragment, u skladu s patentni m zahtjevom l , naznačeno time što sadrži varijabilna područje lakog lanca, koje sadrži aminokiselinski slijed kao što je iznijet u SEQ ID NO: 19 i dodatno sadrži varijabilna područje teškog lanca, koje se bira iz aminokiselinskog slijeda kao što je iznijet u SEQ ID NO: 21 i 52.
3. Ljudsko monoklonsko protutijela, ili njegov fragment, u skladu s patentni m zahtjevom l , naznačeno time što sadrži laki lanac koji sadrži aminokiselinski slijed kao što je iznijet u SEQ ID NO: 34 i sadrži teški lanac koji sadrži aminokiselinski slijed kao što je iznijet u SEQ ID NO: 35.
4. Fragment ljudskog monoklonskog protutijela u skladu s bilo kojim od patentnih zahtjeva l do 3, naznačen time što je navedeni fragment scFv, Fv, dijatijelo, tandemno dijatijelo, Fab, Fab ' ili F(ab)2.
5. Polinukleotidna molekula, naznačena time što sadrži nukleotidni slijed koji kodira ljud sko monoklonsko protutijela, ili njegov fragment, kao što je iznijet u bilo kojem od patentnih zahtjeva 1-3.
6. Farmaceutski pripravak, naznačen time što sadrži ljudsko monoklonsko protutijela, ili njegov fragment, u skladu s bilo kojim od patentnih zahtjeva 1-4 ili polinukleotidnu molekulu u skladu s patentnim zahtjevom 5.
7. Ljudsko monoklonsko protutijela, ili njegov fragment, u skladu s bilo kojim od patentnih zahtjeva 1-4 ili polinukleotidna molekula u skladu s patentnim zahtjevom 5, naznačeni time što mogu sadržavat i jedno ili više dodatnih protuupalnih sredstava, namijenjenih upotrebi u postupku liječenja upalnih bolesti.
8. Ljudsko monoklonsko protutijela, ili njegov fragment, ili polinukleotidna molekula namijenjeni upotrebi u skladu s patentnim zahtjevom 7, naznačeni time što se navedene upalne bolesti bira iz skupine koju čine reumatoidni artritis (RA) (uključujući RA otporan na liječenje neutralizatorima TNFu), astma, multipla skleroza (MS), kronična opstruktivna plućna bolest (COPD), akutni sindrom dišnog distresa (ARDS), idiopatska plućna fibroza (IPF), upalna crijevna bolest (lBD), uveiti s, degeneracija makule, koliti s, psorijaza, Wallerova degeneracija, antifosfolipidni sindrom (APS), akutni koronarni sindrom, restenoza, ateroskleroza, recidivirajući polihondritis (RP), akutni ili kronični hepatiti s, neuspjeli ortopedski usadci , glomerulonefritis, lupus ili autoimuni poremećaji .
9. Ljudsko monoklonsko protutijela, ili njegov fragment, u skladu s bilo kojim od patentnih zahtjeva 1-4 ili polinukleotidna molekula u skladu s patentnim zahtjevom 5, naznačeni time što mogu sadržavati jedno ili više dodatnih antitumorskih sredstava, namijenjenih upotrebi u postupku liječenja tumors kih bolesti ili drugih stanja s odgođenom staničnom apoptozom , povećanim preživljenjem ili proliferacijom stanica.
10. Lj ud sko mon okl on sko protutijela, i l i njegov fragment, ili polinukl eotidna m o l ekula na mijenjeni upotrebi u s kladu s patentni m zahtjevom 9, n az načen i ti me što je naved ena tu m orska bol est rak.
11. Ljud sko mon okl on s ko protutijela, i l i njegov fragment, ili polinukl eotidna m o l ekul a namijenjeni upotrebi u skl adu s patentnim zahtjevo m l O, nazn ačen i t ime što je naved eni rak l euke mija, multipli mijel o m , ka rcin o m želuca ili karc in om kože.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05008410 | 2005-04-18 | ||
| EP06724392.3A EP1874819B1 (en) | 2005-04-18 | 2006-04-18 | Antibody neutralizers of human granulocyte macrophage colony stimulating factor |
| PCT/EP2006/003528 WO2006111353A2 (en) | 2005-04-18 | 2006-04-18 | Antibody neutralizers of human granulocyte macrophage colony stimulating factor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02191B true ME02191B (me) | 2016-02-20 |
Family
ID=37115507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2015-111A ME02191B (me) | 2005-04-18 | 2006-04-18 | Protutijela koja neutraliziraju ljudski čimbenik stimuliranja kolonija makrofaga |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US8017748B2 (me) |
| EP (2) | EP1874819B1 (me) |
| JP (1) | JP5085533B2 (me) |
| KR (2) | KR20150091193A (me) |
| CN (2) | CN103342751B (me) |
| AU (1) | AU2006237159B2 (me) |
| BR (1) | BRPI0608281B8 (me) |
| CA (1) | CA2605402C (me) |
| CY (1) | CY1116632T1 (me) |
| DK (1) | DK1874819T3 (me) |
| EA (2) | EA017420B9 (me) |
| ES (1) | ES2545769T3 (me) |
| HR (1) | HRP20150773T1 (me) |
| HU (1) | HUE025134T2 (me) |
| IL (2) | IL186486A0 (me) |
| ME (1) | ME02191B (me) |
| MX (1) | MX2007012569A (me) |
| NO (1) | NO344249B1 (me) |
| NZ (1) | NZ562093A (me) |
| PL (1) | PL1874819T3 (me) |
| PT (1) | PT1874819E (me) |
| RS (1) | RS54127B1 (me) |
| RU (2) | RU2458071C2 (me) |
| SG (1) | SG161292A1 (me) |
| SI (1) | SI1874819T1 (me) |
| UA (1) | UA94403C2 (me) |
| WO (1) | WO2006111353A2 (me) |
| ZA (1) | ZA200708201B (me) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0608281B8 (pt) | 2005-04-18 | 2021-05-25 | Amgen Res Munich Gmbh | anticorpo monoclonal humano ou seu fragmento, seu uso no tratamento de doenças inflamatórias, bem como composição farmacêutica que o compreende |
| JP4736037B2 (ja) * | 2005-10-26 | 2011-07-27 | 株式会社イーベック | ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分 |
| US7741450B2 (en) | 2006-02-08 | 2010-06-22 | Morphotek Inc. | Antibodies to GM-CSF |
| WO2008063898A2 (en) * | 2006-11-08 | 2008-05-29 | Kalobios Pharmaceuticals, Inc. | Methods of treating idiopathic thrombocytopenia purpura using a gm-csf antagonist |
| US8398972B2 (en) | 2006-11-21 | 2013-03-19 | Kalobios Pharmaceuticals, Inc. | Methods of treating dementia using a GM-CSF antagonist |
| CA2677356A1 (en) * | 2007-02-08 | 2008-08-14 | Zhiqiang An | Antibodies specific for dkk-1 |
| CN101687926A (zh) * | 2007-05-23 | 2010-03-31 | 哮喘和气道Crc有限公司 | 中和抗体 |
| TW200918553A (en) * | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| CN104072613A (zh) * | 2007-11-13 | 2014-10-01 | Evec股份有限公司 | 与hGM-CSF结合的单克隆抗体及包含它的药物组合物 |
| KR102057826B1 (ko) * | 2008-04-11 | 2019-12-20 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| WO2009134805A2 (en) * | 2008-04-28 | 2009-11-05 | Kalobios Pharmaceuticals, Inc. | Antibodies to granulocyte-macrophage colony-stimulating factor |
| CA2717987C (en) * | 2008-04-29 | 2018-11-13 | Micromet Ag | Inhibitors of gm-csf and il-17 for therapy |
| RU2366422C1 (ru) * | 2008-05-19 | 2009-09-10 | Государственное учреждение Научно-исследовательский институт фармакологии Томского научного центра Сибирского отделения Российской Академии медицинских наук (ГУ НИИ фармакологии ТНЦ СО РАМН) | Способ коррекции депрессии гранулоцитопоэза при цитостатическом воздействии |
| CA2747206C (en) | 2008-12-22 | 2018-04-24 | The University Of Melbourne | Pain treatment |
| CN102271705A (zh) * | 2008-12-22 | 2011-12-07 | 墨尔本大学 | 骨关节炎治疗 |
| US20120116059A1 (en) * | 2009-05-05 | 2012-05-10 | Morphosys Ag | Treatment For M Treatment For Multiple Sclerosis |
| MX352889B (es) | 2011-02-25 | 2017-12-13 | Chugai Pharmaceutical Co Ltd | Anticuerpo de fc especifico para fcyriib. |
| CN103827143A (zh) | 2011-07-06 | 2014-05-28 | 莫弗系统股份公司 | 抗cd20抗体和抗gm-csf抗体的治疗性组合产品及其用途 |
| WO2013090989A1 (en) | 2011-12-22 | 2013-06-27 | Csl Limited | Method of treating inflammatory bowel disease |
| WO2014004549A2 (en) | 2012-06-27 | 2014-01-03 | Amgen Inc. | Anti-mesothelin binding proteins |
| WO2014068029A1 (en) | 2012-10-31 | 2014-05-08 | Takeda Gmbh | Lyophilized formulation comprising gm-csf neutralizing compound |
| AR093297A1 (es) | 2012-10-31 | 2015-05-27 | Amgen Res Munich Gmbh | Formulacion liquida que comprende un compuesto neutralizante de gm-csf |
| US20160024200A1 (en) * | 2013-03-14 | 2016-01-28 | John Schrader | Human monoclonal antibodies that neutralize bioactivity of granulocyte macrophage colony-stimulating factor and methods and uses thereof |
| US10745475B2 (en) * | 2013-08-30 | 2020-08-18 | Takeda Gmbh | Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics |
| WO2015028666A1 (en) * | 2013-08-30 | 2015-03-05 | Takeda Gmbh | Neutralizing antibody or a fragment thereof specifically binding primate gm-csf for use in the treatment and/or prevention of psoriasis |
| CN105813654B (zh) | 2013-10-11 | 2019-05-31 | 美国政府(由卫生和人类服务部的部长所代表) | Tem8抗体及其用途 |
| WO2015103549A1 (en) | 2014-01-03 | 2015-07-09 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Neutralizing antibodies to hiv-1 env and their use |
| KR102385802B1 (ko) | 2014-05-07 | 2022-04-13 | 다케다 야쿠힝 고교 가부시키가이샤 | Gm-csf 중화 화합물을 포함하는 액체 제제 |
| WO2016077789A1 (en) | 2014-11-14 | 2016-05-19 | The Usa, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to ebola virus glycoprotein and their use |
| WO2016079276A1 (en) * | 2014-11-21 | 2016-05-26 | Takeda Gmbh | Use of an anti-gm-csf antagonist and an anti-ccr2 antagonist in the treatment of an infectious disease |
| WO2016079277A1 (en) * | 2014-11-21 | 2016-05-26 | Takeda Gmbh | Use of an anti-gm-csf antagonist in the treatment of an infectious disease |
| WO2016138160A1 (en) | 2015-02-24 | 2016-09-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use |
| GB201503139D0 (en) * | 2015-02-25 | 2015-04-08 | Univ Leicester | Diagnostic and therapeutic target |
| ES2789348T3 (es) | 2015-03-20 | 2020-10-26 | Us Health | Anticuerpos neutralizantes para GP120 y sus usos |
| CA2997809A1 (en) | 2015-10-07 | 2017-04-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia |
| GB201519331D0 (en) * | 2015-11-02 | 2015-12-16 | Glaxosmithkline Ip Dev Ltd | Treatment paradigm |
| WO2017079479A1 (en) | 2015-11-03 | 2017-05-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human | Neutralizing antibodies to hiv-1 gp41 and their use |
| WO2017192589A1 (en) | 2016-05-02 | 2017-11-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to influenza ha and their use and identification |
| CN106872428A (zh) * | 2017-02-07 | 2017-06-20 | 远见生物科技（上海）有限公司 | 一种用于检测中性粒细胞呼吸爆发功能的试剂盒 |
| EP3580235B1 (en) | 2017-02-10 | 2024-05-01 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use |
| US10927168B2 (en) | 2017-10-02 | 2021-02-23 | Humanicen, Inc. | Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab |
| US11130805B2 (en) | 2017-10-02 | 2021-09-28 | Humanigen, Inc. | Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist |
| AU2018345751A1 (en) | 2017-10-02 | 2020-05-07 | Humanigen, Inc. | Methods of treating immunotherapy-related toxicity using a GM-CSF antagonist |
| US10899831B2 (en) | 2017-10-02 | 2021-01-26 | Humanigen, Inc. | Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity |
| JP7138896B2 (ja) | 2017-10-24 | 2022-09-20 | 株式会社Asm | 低包接率ポリロタキサンの製造方法 |
| EP3724223A1 (en) | 2018-01-02 | 2020-10-21 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Neutralizing antibodies to ebola virus glycoprotein and their use |
| RU2020130795A (ru) | 2018-02-21 | 2022-03-21 | Дзе Юнайтед Стэйтс Оф Америка, Эс Репрезентед Бай Дзе Секретэри, Департмент Оф Хелт Энд Хьюман Сервисиз | Нейтрализующие антитела к env вич-1 и их применение |
| JP7603580B2 (ja) | 2018-10-15 | 2024-12-20 | エリクシロン・イミュノセラピューティクス・（ホンコン）・リミテッド | 顆粒球マクロファージコロニー刺激因子に対する抗体及びそれらの使用 |
| US11078264B2 (en) | 2018-10-17 | 2021-08-03 | University Of Connecticut | Inhibiting granulocyte macrophage-colony stimulating factor (GM-CSF) prevents preterm birth |
| US20220089694A1 (en) | 2018-12-20 | 2022-03-24 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof |
| EP3962523A2 (en) | 2019-05-03 | 2022-03-09 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use |
| WO2020236974A1 (en) | 2019-05-21 | 2020-11-26 | University Of Georgia Research Foundation, Inc. | Antibodies that bind human metapneumovirus fusion protein and their use |
| WO2021003297A1 (en) | 2019-07-02 | 2021-01-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies that bind egfrviii and their use |
| WO2021204649A1 (en) | 2020-04-06 | 2021-10-14 | Glaxosmithkline Intellectual Property Development Limited | Gm-csf antagonists for use in the treatment of severe pulmonary covid-19, cytokine release syndrome and/or acute respiratory distress syndrome |
| WO2022132904A1 (en) | 2020-12-17 | 2022-06-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies targeting sars-cov-2 |
| AU2022221297A1 (en) | 2021-02-09 | 2023-08-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibodies targeting the spike protein of coronaviruses |
| WO2022173689A1 (en) | 2021-02-09 | 2022-08-18 | University Of Georgia Research Foundation, Inc. | Human monoclonal antibodies against pneumococcal antigens |
| CA3232223A1 (en) | 2021-09-17 | 2023-03-23 | Ying Fu | Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies |
| KR20240142563A (ko) | 2022-02-10 | 2024-09-30 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 코로나바이러스를 광범위하게 표적으로 하는 인간 모노클로날 항체 |
| EP4499228A1 (en) | 2022-03-28 | 2025-02-05 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Neutralizing antibodies to hiv-1 env and their use |
| WO2024030829A1 (en) | 2022-08-01 | 2024-02-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies that bind to the underside of influenza viral neuraminidase |
| WO2024054822A1 (en) | 2022-09-07 | 2024-03-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Engineered sars-cov-2 antibodies with increased neutralization breadth |
| WO2024064826A1 (en) | 2022-09-22 | 2024-03-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use |
| WO2024137381A1 (en) | 2022-12-19 | 2024-06-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies for treating sars-cov-2 infection |
| WO2024138151A1 (en) | 2022-12-22 | 2024-06-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Ebolavirus (sudan and zaire) antibodies from non-human primates and human vaccinees |
| WO2024243355A1 (en) | 2023-05-24 | 2024-11-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies that target the rh5 complex of blood-stage plasmodium falciparum |
| WO2025014896A1 (en) | 2023-07-07 | 2025-01-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Humanized 40h3 antibody |
| AU2024300009A1 (en) | 2023-07-21 | 2026-01-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bispecific antibodies that broadly target coronaviruses |
| WO2025106427A1 (en) | 2023-11-14 | 2025-05-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing and protective monoclonal antibodies against respiratory syncytial virus (rsv) |
| WO2025117384A1 (en) | 2023-12-01 | 2025-06-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Broadly neutralizing influenza hemagglutinin stem-directed antibodies |
| WO2025137284A2 (en) | 2023-12-21 | 2025-06-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Broadly neutralizing antibodies against sars-cov-2 and sars-cov variants |
| WO2026030473A1 (en) | 2024-07-31 | 2026-02-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | West nile virus neutralizing monoclonal antibodies |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8624899D0 (en) | 1986-10-17 | 1986-11-19 | Sandoz Ltd | Monoclonal antibodies |
| US5070013A (en) * | 1988-05-31 | 1991-12-03 | Schering Corporation | Immunochemical assay for human granulocyte-macrophage colony stimulating factor |
| CA2060741A1 (en) * | 1991-02-11 | 1992-08-12 | Robert S. Greenfield | Gm-csf inhibiting oligopeptides |
| GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
| EP0975748B1 (en) | 1997-04-23 | 2006-03-29 | Universität Zürich | Methods for identifying nucleic acid molecules encoding (poly)peptides that interact with target molecules |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| US7112324B1 (en) | 1998-04-21 | 2006-09-26 | Micromet Ag | CD 19×CD3 specific polypeptides and uses thereof |
| US7157091B1 (en) * | 1999-06-18 | 2007-01-02 | Ludwig Institute For Cancer Research | MAGE-A1 peptides presented by HLA class II molecules |
| US7101551B2 (en) | 2000-02-14 | 2006-09-05 | Mitsubishi Pharma Corporation | Remedies for hepatitis C |
| US20050271663A1 (en) * | 2001-06-28 | 2005-12-08 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| JP2006500905A (ja) | 2002-02-13 | 2006-01-12 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | ヒト化ｇｍ−ｃｓｆ抗体 |
| ATE435238T1 (de) | 2004-05-05 | 2009-07-15 | Micromet Ag | Herstellung eines einkettigen fv antikörperfragments |
| BRPI0608281B8 (pt) * | 2005-04-18 | 2021-05-25 | Amgen Res Munich Gmbh | anticorpo monoclonal humano ou seu fragmento, seu uso no tratamento de doenças inflamatórias, bem como composição farmacêutica que o compreende |
| RU2447085C2 (ru) | 2005-05-18 | 2012-04-10 | МорфоСис АГ | Анти-gm-csf антитела и их применение |
| US7741450B2 (en) | 2006-02-08 | 2010-06-22 | Morphotek Inc. | Antibodies to GM-CSF |
-
2006
- 2006-04-18 BR BRPI0608281A patent/BRPI0608281B8/pt active IP Right Grant
- 2006-04-18 SG SG201002699-5A patent/SG161292A1/en unknown
- 2006-04-18 CN CN201310231969.5A patent/CN103342751B/zh not_active Expired - Lifetime
- 2006-04-18 UA UAA200712125A patent/UA94403C2/ru unknown
- 2006-04-18 EA EA200901500A patent/EA017420B9/ru unknown
- 2006-04-18 ME MEP-2015-111A patent/ME02191B/me unknown
- 2006-04-18 AU AU2006237159A patent/AU2006237159B2/en not_active Expired
- 2006-04-18 NZ NZ562093A patent/NZ562093A/en unknown
- 2006-04-18 RU RU2007138341/10A patent/RU2458071C2/ru active
- 2006-04-18 DK DK06724392.3T patent/DK1874819T3/en active
- 2006-04-18 JP JP2008506992A patent/JP5085533B2/ja not_active Expired - Lifetime
- 2006-04-18 WO PCT/EP2006/003528 patent/WO2006111353A2/en not_active Ceased
- 2006-04-18 PL PL06724392T patent/PL1874819T3/pl unknown
- 2006-04-18 ES ES06724392.3T patent/ES2545769T3/es not_active Expired - Lifetime
- 2006-04-18 HR HRP20150773TT patent/HRP20150773T1/hr unknown
- 2006-04-18 RS RS20150497A patent/RS54127B1/sr unknown
- 2006-04-18 SI SI200631960T patent/SI1874819T1/sl unknown
- 2006-04-18 US US11/918,368 patent/US8017748B2/en active Active
- 2006-04-18 HU HUE06724392A patent/HUE025134T2/en unknown
- 2006-04-18 CN CN2006800188584A patent/CN101184777B/zh not_active Expired - Lifetime
- 2006-04-18 CA CA2605402A patent/CA2605402C/en not_active Expired - Lifetime
- 2006-04-18 PT PT67243923T patent/PT1874819E/pt unknown
- 2006-04-18 EP EP06724392.3A patent/EP1874819B1/en not_active Expired - Lifetime
- 2006-04-18 KR KR1020157020152A patent/KR20150091193A/ko not_active Abandoned
- 2006-04-18 KR KR1020077026929A patent/KR101704809B1/ko not_active Expired - Lifetime
- 2006-04-18 EP EP12159883A patent/EP2468774A3/en not_active Ceased
- 2006-04-18 MX MX2007012569A patent/MX2007012569A/es active IP Right Grant
- 2006-04-18 EA EA200702008A patent/EA013162B1/ru unknown
-
2007
- 2007-09-20 ZA ZA200708201A patent/ZA200708201B/en unknown
- 2007-10-08 IL IL186486A patent/IL186486A0/en not_active IP Right Cessation
- 2007-11-12 NO NO20075802A patent/NO344249B1/no unknown
-
2011
- 2011-08-04 US US13/198,558 patent/US9067993B2/en active Active
-
2012
- 2012-04-20 RU RU2012115683/10A patent/RU2012115683A/ru not_active Application Discontinuation
- 2012-06-14 IL IL220412A patent/IL220412A/en active IP Right Grant
-
2015
- 2015-05-21 US US14/718,923 patent/US10138297B2/en active Active
- 2015-08-20 CY CY20151100731T patent/CY1116632T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02191B (me) | Protutijela koja neutraliziraju ljudski čimbenik stimuliranja kolonija makrofaga | |
| ES2902063T3 (es) | Proteínas de unión a interleucina-13 | |
| JP2013539369A5 (me) | ||
| HRP20181085T1 (hr) | Protutijela koja vežu il-4 i/ili il-13 i njihova uporaba | |
| ME02734B (me) | Antitelo koje vezuje il-17a i il-17f | |
| JP2014111644A5 (me) | ||
| JP2009545319A5 (me) | ||
| JP2011518857A5 (me) | ||
| HRP20150937T1 (hr) | Pentaspecifiäśno protutijelo | |
| JP2016128474A5 (me) | ||
| HRP20161069T1 (hr) | Molekule antitijela koje vezuju il-17a i il-17f | |
| HRP20201113T1 (hr) | Vežući proteini protiv lag-3 | |
| JP2008542321A5 (me) | ||
| HRP20160638T1 (hr) | Antigen vezujući proteini sposobni vezati timusni stromalni limfopoetin | |
| JP2018519364A5 (me) | ||
| HRP20140512T1 (hr) | Humana antitijela s visokim afinitetom za humani il-4 receptor | |
| JP2013520996A5 (me) | ||
| JP2012503979A5 (me) | ||
| RU2007143996A (ru) | Антитела против il2 | |
| HRP20230605T1 (hr) | Protutijela protiv interferona beta i njihova upotreba | |
| JP2011512120A5 (me) | ||
| JP2023551935A5 (me) | ||
| AU2024235509A1 (en) | Antibody specifically binding to interleukin-13, and use thereof | |
| NZ748616B2 (en) | Antibodies to alpha-synuclein and uses thereof | |
| HK1128495A (en) | Interleukin -13 binding proteins |